The RAGE-Mediated Transcytotic Pump Enhancement Strategy proposes that therapeutic antibody delivery to the CNS can be optimized by targeting the receptor for advanced glycation end products (RAGE) pathway while simultaneously exploiting its bidirectional transport capabilities through engineered ligand competition. Unlike LRP1-dependent endocytic mechanisms which rely on endosomal escape, this approach leverages RAGE's unique transcytotic shuttling system that naturally operates as a molecular pump across the blood-brain barrier. The strategy involves conjugating therapeutic antibodies to high-mobility group box 1 (HMGB1) mimetic peptides or engineered S100 protein fragments that selectively bind RAGE with enhanced affinity compared to endogenous inflammatory ligands. The critical innovation lies in creating competitive inhibition of pro-inflammatory RAGE signaling while simultaneously hijacking the receptor's constitutive transcytotic machinery for antibody transport. This mechanism addresses BBB penetration limitations while providing anti-inflammatory benefits by displacing pathogenic RAGE ligands such as advanced glycation end products and amyloid oligomers.

The RAGE-Mediated Transcytotic Pump Enhancement Strategy proposes that therapeutic antibody delivery to the CNS can be optimized by targeting the receptor for advanced glycation end products (RAGE) pathway while simultaneously exploiting its bidirectional transport capabilities through engineered ligand competition. Unlike LRP1-dependent endocytic mechanisms which rely on endosomal escape, this approach leverages RAGE's unique transcytotic shuttling system that naturally operates as a molecular pump across the blood-brain barrier. The strategy involves conjugating therapeutic antibodies to high-mobility group box 1 (HMGB1) mimetic peptides or engineered S100 protein fragments that selectively bind RAGE with enhanced affinity compared to endogenous inflammatory ligands. The critical innovation lies in creating competitive inhibition of pro-inflammatory RAGE signaling while simultaneously hijacking the receptor's constitutive transcytotic machinery for antibody transport. This mechanism addresses BBB penetration limitations while providing anti-inflammatory benefits by displacing pathogenic RAGE ligands such as advanced glycation end products and amyloid oligomers. The RAGE receptor, constitutively expressed on brain capillary endothelium and upregulated during neuroinflammation, provides a stress-responsive transport pathway with inflammation-dependent kinetics. By modulating LDLR expression levels in brain endothelial cells through targeted gene therapy, the cholesterol-sensing machinery can be engineered to cross-regulate RAGE expression and transcytotic activity, creating a metabolically-linked transport enhancement system. This approach transforms inflammatory RAGE signaling from a pathogenic pathway into a therapeutic delivery conduit, potentially achieving sustained CNS antibody concentrations while simultaneously reducing neuroinflammation. The strategy is particularly relevant for Alzheimer's disease where RAGE-mediated amyloid influx contributes to pathology, allowing therapeutic antibodies to compete directly with pathogenic substrates at the transport level.